Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 13 4 2019 10 01 174 182 EN Shahrzad Soleymani Fard Hematology, Oncology and Stem Cell Transplantation Research Institute, Tehran University of Medical Sciences, Tehran, Iran Masoud Sotoudeh Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Mansour Yazdanbod Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Ardeshir Ghavamzadeh Hematology, Oncology and Stem Cell Transplantation Research Institute, Tehran University of Medical Sciences, Tehran, Iran Reza Malekzadeh Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Marjan Yaghmaie Hematology, Oncology and Stem Cell Transplantation Research Institute, Tehran University of Medical Sciences, Tehran, Iran Seyed Asadollah Mousavi Hematology, Oncology and Stem Cell Transplantation Research Institute, Tehran University of Medical Sciences, Tehran, Iran Seyed H. Ghaffari Hematology, Oncology and Stem Cell Transplantation Research Institute, Tehran University of Medical Sciences, Tehran, Iran Kamran Alimoghaddam Hematology, Oncology and Stem Cell Transplantation Research Institute, Tehran University of Medical Sciences, Tehran, Iran 2019 07 07 2019 07 31 Background: It is well-known that Aurora kinase A (AURKA) shows oncogenic properties in various tumor types including gastric cancer (GC). Moreover, previous studies have demonstrated that AURKA has a specific androgen receptor (AR) binding site in its promoter; thus, it could be regulated by AR. Since it has been shown that AR overexpresses in gastric cancer (GC) as a male-predominant tumor, the goal of this study was to evaluate the association between AR and AURKA and its prognostic value in GC patients. Materials and Methods: We assessed the expression profile of AURKA in 60 fresh GC and adjacent non-tumor tissues and 50 normal gastric specimen by qRT-PCR, and investigated the association of AURKA expression with clinicopathological features. Furthermore, we evaluated possible correlation between AURKA and AR to elucidate a novel prognostic marker using Kaplan-Meier method and Cox regression model. Conclusion: Among GC patients, 65% (39/60) overexpressed AURKA relative to normal gastric tissues. AURKA overexpression was significantly correlated with the AR overexpression in GC patients. Although AURKA expression alone was not remarkably associated with poor outcome, we provided some evidence that combined evaluation of AURKA and AR expression could independently predict survival of GC patients adjusted for other variables (HR=1.7, CI=1.314-3.833 p=0.042). Conclusion: These results indicate that AR and AURKA may crosstalk to promote GC progression. Our findings have clinical importance because they suggest simultaneous assessment of AURKA and AR expression as a novel potential prognostic marker. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1155 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1155/797

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 13 4 2019 10 01 201 207 EN Abdella Birhan Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Addis Ababa University (AAU), Addis Ababa, Ethiopia Tamrat Assefa Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Addis Ababa University (AAU), Addis Ababa, Ethiopia Alemseged Beyene Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Addis Ababa University (AAU), Addis Ababa, Ethiopia Pacifique Ndayishimiye Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili Health and Allied Sciences (MUHAS), Dar Es Salaam, Tanzania Minyahil Woldu Department of Pharmacology and 1) Clinical Pharmacy, School of Pharmacy, Addis Ababa University (AAU), Addis Ababa, Ethiopia. AND Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili Health and Allied Sciences (MUHAS), Dar Es Salaam, Tanzania 2019 01 21 2019 04 29 Deep vein thrombosis (DVT) is a major health problem affecting a significant portion of population. Primary complications are Pulmonary Embolism (PE) in the short term and Post-Thrombotic Syndrome (PTS) in the long term. Thrombolytic drugs act by activating plasminogen which in turn forms the enzyme plasmin. Plasmin consequently degrades blood clots by breaking down the fibrin molecules which make up the clots help to degrade the already formed clot. They can be used using different route of administration, doses and durations. The purpose of this systematic review was to assess the outcome of thrombolytic therapy in terms of the efficacy, safety and effectiveness of the medicines. Electronic searches of databases (MEDLINE and Google Scholar) were queried for articles written in English since 2000 GC. A total of 760 results were obtained using the search keys, and after excluding duplicates, 275 articles were selected. Finally, 9 randomized controlled trials (RCTs) which met the language of publication, study design and exclusion criteria were included in this systematic review. The data were obtained from nine trials (6 countries), providing a study-level data of 1309 participants. Almost all studies revealed that thrombolytic treatment was effective in the management of acute DVT. In most of the studies, the rate of rethrombosis was lower in case of thrombolytic than standard management. Hence, addition of thrombolytic results in persistence and increases the clinical benefits. Thrombolytic therapy was very effective in reversing closed veins, in boosting the patency rate, while reflux was higher in patients treated with anticoagulants. Thrombolytic offers potential advantages over the standard treatment of DVT by reducing the proportion of patients with chronic disabling leg symptoms (such as PTS) by triple in the longer term. However, the incident of major bleeding was higher in patients receiving thrombolytics https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1061 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1061/801

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 13 4 2019 10 01 172 173 Hassan Mansouritorghabeh Allergy Research Centre, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2019 07 15 2019 09 30 This is a letter to the editor without abstract. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1157 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1157/805

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 13 4 2019 10 01 183 188 Monica Rivera Franco Stem Cell Transplantation Program, Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico Eucario León-Rodríguez Stem Cell Transplantation Program, Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico Diana Gómez-Martín Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico 2019 04 10 2019 05 12 Background: Acute graft-versus-host disease (aGVHD) is an important cause of death following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The association between cholesterol and aGVHD was previously described potentially resulting from pro-inflammatory responses associated with hypercholesterolemia. The aim of this study was to correlate T-cell subsets in donor bone marrow (BM) samples with their levels of cholesterol and associate these results with recipients who developed aGVHD and those who did not. Materials and Methods: A prospective study was performed in 39 donor samples. T-cell subsets were analyzed by flow cytometry. Results: Eleven (28%) donors had hypercholesterolemia. Donor samples with hypercholesterolemia had less Tregs compared to donors with normal levels of cholesterol (22.69 (IQR=30.6) cells/µL vs 52.62 (IQR=44.68) cells/µL, p=0.04). Among all the cohort, aGVHD was observed in 21%: 36% from donors with hypercholesterolemia versus 14% from donors with normal levels of cholesterol.   Conclusion: As we described the association between hypercholesterolemia and diminished Tregs, our results might suggest that normalizing the levels of total cholesterol in the donor, prior performing allo-HSCT, might be an effective approach to diminish the risk of the receptor to develop aGVHD. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1109 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1109/798

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 13 4 2019 10 01 189 195 Ali Karimi Rozveh School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran Alireza Nasrabadi School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran Shahrzad Ghiyasvandian School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran Leila Sayadi School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran Mohammad Vaezi Hematology- Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Reza Amjad Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran 2019 04 02 2019 07 15 Background: Hematopoetic stem cell transplantation is considered as a standard treatment for cancer patients to stay hopeful toward treatment outcome. However, these patients experience many complications which might affect different aspects of their life. The aim of this study was to investigate the lived experience of patients after hematopoetic stem cell transplantation and introduce supportive care strategies. Materials and Methods: In this study, Van Manen’s Hermeneutic phenomenological approach was used. Eleven patients (7 males and 4 females) were chosen by targeted sampling from visitors of Shariati Hospital’s outpatient clinic. Semi-structured interviews were conducted and the final data were analyzed by MAXQDA 10 software. Results: Data analysis revealed that the main theme was resiliency with two sub-themes of “not surrendering to disease” and “feeling closer to God”. Conclusion: Participants declared that transplantation was like a second chance for life and considered this opportunity as a gift from God to overcome their disease. According to our findings, spirituality aids can help patients control the disturbances following HSCT and health professionals can use constructive strategies to support patients with spiritual needs. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1103 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1103/799

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 13 4 2019 10 01 196 200 Mahrokh Imanian Medical Surgical Nursing, Jahrom University of Medical Sciences, Jahrom, Iran Mahsa Imanian Medical Surgical Nursing, Jahrom University of Medical Sciences, Jahrom, Iran Mahdi Karimyar Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran 2019 01 23 2019 09 17 Background: Breast cancer survivors make up a growing population facing treatment that poses long – standing adverse effects including chemotherapy- related sleep disorders and fatigue. There is limited knowledge of patients' lived experiences of chemotherapy- induced sleep disorders and fatigue. The aim of this study was to explore sleep quality and fatigue among breast cancer patients undergoing chemotherapy Materials and Methods: One hundred fifteen patients were included in this census-based cross-sectional study. Data were collected through the Pittsburgh Sleep Quality Index and Brief Fatigue Inventory four days after the chemotherapy session. Statistical analysis was carried out using SPSS software version 13 and P<0.05 was considered significant in all tests. Results: The mean hours of sleep were 5.6±1.83 in the range of 2 to 10 hours. The mean score of fatigue of participants was 5.59±1.67. Based on the cutting point, 57.4%, 20.9%, and 21.7% of participants had a moderate (4-6.9), mild (0.1-3.9), and severe (7-9.9) level of fatigue, respectively. The mean score of sleep quality among the participants was equal to 14.06±3.06, with a maximum and minimum of 7 and 21. The results of Spearman correlation coefficient showed that there is a significant relationship between fatigue and quality of sleep )0.210). Conclusion: Since the study findings revealed that patients with breast cancer undergoing chemotherapy experience different degrees of sleep disorders and fatigue and due to the little attention paid to this issue in the medical field, there is a need for more detailed studies to improve the quality of sleep and reduce fatigue in these patients.    https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1063 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1063/800

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 13 4 2019 10 01 208 219 Faten Abo-Aziza Department of Parasitology and Animal Diseases, Veterinary Research Division, National Research Center, Giza, Egypt A.A. Zaki Department of Physiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt Amany Amer Department of Zoology, Faculty of Women for Arts, Science and Education, Ain Shams University, Cairo, Egypt Rania Lotfy Department of Zoology, Faculty of Women for Arts, Science and Education, Ain Shams Univers 2015 10 29 2015 12 17 Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations. Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender. Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 ± .01 for oral iron chelators versus 0.81 ± .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males. Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in. .  https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/487 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/487/516

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 10 4 2016 10 06 232 235 EN Roshanak Hasheminasab Zavareh Department of Internal Medicine, Rasoul Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran Hassan Riahi Beni Department of Cardiovascular Diseases, Rasoul Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran Aida Iranpour Department of Internal Medicine, Rasoul Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran Mojgan Alam Samimi Department of Hematology and Oncology, Rasoul Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran Alireza Sadeghipour Department of Pathology, Rasoul Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran Seyedeh Nina Alavi Niakou Department of Internal Medicine, Rasoul Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran 2015 10 28 2015 10 29 Leiomyosarcoma is one of the soft tissue sarcomas that could originate from different parts of body and are mostly presented as retropritoneal mass. Leiomyosarcomas of vascular origin are particularly rare tumors occurring mainly in inferior vena cava (IVC). Here, we report the case of a 35-year-old male patient who presented with ascites and jaundice. Further evaluation revealed large hepatic and cardiac masses with extension to IVC. Since it was not possible to determine the point of origin of leiomyosarcoma, the patient received chemotherapy under diagnosis of metastatic leiomyosarcoma but unfortunately passed away. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/484 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/484/517

Tehran University of Medical Sciences International Journa